Skip to main content

Table 1 Multivariate analysis of tissue microarray cohort

From: STAG2 is a clinically relevant tumor suppressor in pancreatic ductal adenocarcinoma

Model Variable P-value Hazard ratio
(95% CI)
A. Clinical pathology and STAG2 STAG2 (< 95%) 0.017 1.421 (1.064-1.898)
  T stage (1/2) 0.729 1.066 (0.743-1.529)
  N stage (N0) 0.196 0.826 (0.618-1.104)
  Grade (1/2) 0.013 0.711 (0.544-0.93)
  Sex (female) 0.865 1.023 (0.785-1.333)
  Margin involvement (negative) 0.297 0.852 (0.63-1.151)
  M stage (M0) 0.132 1.487 (0.887-2.492)
B. Clinical pathology and STAG2 STAG2 (< 95%) 0.017 1.415 (1.064-1.883)
  T stage (1/2) 0.719 1.068 (0.746-1.531)
  N stage (N0) 0.195 0.825 (0.618-1.103)
  Grade (1/2) 0.013 0.713 (0.546-0.931)
  Margin involvement (negative) 0.3 0.853 (0.631-1.152)
  M stage (M0) 0.126 1.494 (0.894-2.497)
C. Clinical pathology and STAG2 STAG2 (< 95%) 0.016 1.42 (1.068-1.888)
  N stage (N0) 0.198 0.827 (0.619-1.105)
  Grade (1/2) 0.014 0.717 (0.55-0.934)
  Margin involvement (negative) 0.321 0.861 (0.64-1.158)
  M stage (M0) 0.131 1.484 (0.889-2.478)
D. Clinical pathology and STAG2 STAG2 (< 95%) 0.014 1.428 (1.074-1.898)
  N stage (N0) 0.185 0.822 (0.616-1.098)
  Grade (1/2) 0.011 0.709 (0.545-0.924)
  M stage (M0) 0.086 1.556 (0.94-2.574)
E. Clinical pathology and STAG2 (final model) STAG2 (< 95%) 0.021 1.394 (1.051-1.849)
  Grade (1/2) 0.007 0.697 (0.536-0.906)
  M stage (M0) 0.061 1.615 (0.979-2.665)
  1. CI, confidence interval.